---
title: "Faeth Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294817471.md"
datetime: "2026-08-04T11:42:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294817471.md)
  - [en](https://longbridge.com/en/news/294817471.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294817471.md)
---

# Faeth Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -2.84, beating the estimate of USD -4.7568.

EBIT: As of FY2026 Q2, the actual value is USD -16.01 M.

### Financial Overview for Q2 2026

#### Cash, Cash Equivalents, and Marketable Securities

As of June 30, 2026, Faeth Therapeutics, Inc. reported cash, cash equivalents, and marketable securities totaling $186.4 million, a significant increase from $21.2 million as of December 31, 2025. Specifically, cash and cash equivalents were $26,903 thousand as of June 30, 2026, compared to $8,668 thousand as of December 31, 2025. Marketable securities stood at $159,538 thousand on June 30, 2026, up from $12,516 thousand on December 31, 2025.

#### Research and Development (R&D) Expenses

R&D expenses for the quarter ended June 30, 2026, were $9,180 thousand, an increase from $2,533 thousand for the same period in 2025. This increase was primarily driven by clinical trial and manufacturing costs supporting the development of PIKTOR, along with higher personnel costs, partially offset by lower clinical trial costs for SNS-101.

#### General and Administrative (G&A) Expenses

G&A expenses for the quarter ended June 30, 2026, amounted to $9,205 thousand, compared to $2,673 thousand during the quarter ended June 30, 2025. The rise in G&A expense was primarily attributable to increased personnel costs and professional fees related to financing and reporting activities.

#### Total Operating Expenses

Total operating expenses for the quarter ended June 30, 2026, were $18,385 thousand, compared to $5,206 thousand for the quarter ended June 30, 2025.

#### Loss from Operations

Loss from operations for the quarter ended June 30, 2026, was - $18,385 thousand, compared to - $5,206 thousand for the same period in 2025.

#### Total Other Income

Total other income for the quarter ended June 30, 2026, was $2,378 thousand, up from $270 thousand for the quarter ended June 30, 2025.

#### Net Loss

Faeth Therapeutics, Inc. reported a net loss of - $16,007 thousand for the quarter ended June 30, 2026, compared with a net loss of - $4,936 thousand for the quarter ended June 30, 2025.

#### Balance Sheet Highlights

Total assets were $189,306 thousand as of June 30, 2026, significantly higher than $22,902 thousand as of December 31, 2025. Total liabilities increased to $9,581 thousand as of June 30, 2026, from $4,310 thousand as of December 31, 2025. Total stockholders’ equity stood at $172,958 thousand on June 30, 2026, compared to $18,592 thousand on December 31, 2025.

#### Operational Metrics and Recent Updates

In April, the first patient was dosed in the Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer. In June, stockholders approved the conversion of Series B preferred stock into common stock, and the company changed its name to Faeth Therapeutics, Inc., beginning trading under the ticker symbol “FTH”. Additionally, Anand Parikh was appointed Chairman, President, and Chief Executive Officer, and Brian Stephenson, Ph.D., CFA, was appointed Chief Financial Officer, with new additions to the board of directors.

#### Outlook / Guidance

Faeth Therapeutics, Inc. anticipates topline results from its Phase 2 PIK-201 trial in endometrial cancer by year-end 2026 and expects to report initial safety and efficacy data from its PIK-101 trial in HR+ breast cancer in 2027. The recent $200 million PIPE financing provides capital to support the multi-nodal hypothesis investigation across various cancers.

### Related Stocks

- [FTH.US](https://longbridge.com/en/quote/FTH.US.md)

## Related News & Research

- [Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments | FTH Stock News](https://longbridge.com/en/news/295928610.md)
- [Faeth Therapeutics files initial beneficial ownership statement for Khosla Ventures VI, L.P](https://longbridge.com/en/news/294108113.md)
- [Faeth Therapeutics CFO Brian C. Stephenson acquires USD 319,293 of common shares](https://longbridge.com/en/news/291473235.md)
- [Faeth Therapeutics CFO Brian C. Stephenson reports $489,159 common share purchase](https://longbridge.com/en/news/291015452.md)
- [Faeth Therapeutics CFO Brian C. Stephenson files initial beneficial ownership statement](https://longbridge.com/en/news/290611234.md)